17,261 trials
Fatty Liver Disease, Nonalcoholic · Nonalcoholic Steatohepatitis · Lipodystrophy
Primary: Liver Histopathology — 6; 5 units on a scale
Pancreatic Cancer
Primary: 2-month Progression-Free Survival Rate — 10; 10 percentage of patients
Idiopathic Pulmonary Fibrosis
Primary: Serum MMP7 Level — -0.15; 0.88 ng/ml — p=0.2072
Ulcerative Colitis
Primary: Number of Participants With Adverse Events — 3 Participants
Pain, Post-operative
Primary: Number of Subjects With Adverse Events — 12; 10; 10 Participants
Myelodysplastic Syndrome
Primary: The Number of Patients Who Achieved a Clinical Response — 5 Participants
Glioblastoma
Primary: Change in pAKT (S473) Immunohistochemistry (IHC) Score From Baseline to Surgery [Cohort 1] — 6; 1; 7; 1 Participants
Medulloblastoma
Primary: Percentage of Participants With Overall Response Rate (ORR) According to Independent Review Committee (IRC) From Date First Participant Randomized, 13-Sep-2013 to Date…
Healthy · Dyspnea
Primary: Subject Rating of Breathing Discomfort (Dyspnea) — 20; 20; 16; 17 units on a scale — p=0.99
Marijuana Dependence
Primary: Urine Drug Screen — 0; 0 Participants
Prostate Cancer
Primary: Number of Participants With Androgen Receptor (AR) Related Mutations — 1 Participants
Insulin Resistance · Type 2 Diabetes Mellitus · Obesity
Primary: Insulin Sensitivity Quantified by Matsuda Index — 5.0; 9.4; 7.2; 7.3 units on a scale — p=0.164
Vitamin D Deficiency
Primary: Level of Serum 25 OHD Level Pre-treatment and Post Treatment — 12.03; 10.36; 37.17; 10.51 ng/mL — p=0.9
Squamous Cell Carcinoma of the Head and Neck
Primary: Percentage of Participants Who Experienced Adverse Events During Treatment. — 96; 96 percentage of patients
Anemia of Chronic Kidney Disease
Primary: Change in Serum Hepcidin With Vitamin D Intervention for Children With Chronic Kidney Disease — 48.2; 75.4 ng/ml